Literature DB >> 30463988

Lysophospholipid G protein-coupled receptor binding parameters as determined by backscattering interferometry.

Hirotaka Mizuno1,2, Yasuyuki Kihara1, Amanda Kussrow3,4, Allison Chen1, Manisha Ray1, Richard Rivera1, Darryl J Bornhop3,4, Jerold Chun5.   

Abstract

Lysophosphatidic acid (LPA) activates cognate G protein-coupled receptors (GPCRs) to initiate biological signaling cascades. Lysophospholipid (LP) receptor binding properties remain incompletely assessed because of difficulties with ligand lipophilicity and lipid "stickiness." These inherent attributes produce high levels of nonspecific binding within cell-membrane preparations used to assess GPCRs, as has been shown in classical binding assays using radiolabeled ligands, making accurate measurements of lipid binding kinetics difficult to achieve. Backscattering interferometry (BSI) is an optical technology that measures molecular binding interactions by reporting changes in the refractive index of a solution after binding events. Here, we report the use of BSI to assess LPA1 for its ability to bind to naturally occurring lipids and a synthetic LPA1 antagonist (ONO-9780307), under both primary- and competition-binding conditions. Assessment of 12 different lipids demonstrated that the known LP ligand, 1-oleoyl-LPA, as well as an endocannabinoid metabolite, anandamide phosphate, are specific ligands for LPA1, whereas other LPs tested were not. Newly determined dissociation constants (Kd values) for orthosteric lipid ligands approximated 10-9 M, substantially lower (i.e., with higher affinity) than measured Kd values in classical binding or cell-based assays. These results demonstrate that BSI may have particular utility in assessing binding interactions between lipid receptors and their lipid ligands and could provide new screening approaches for lipid receptor identification and drug discovery.
Copyright © 2019 Mizuno et al.

Entities:  

Keywords:  binding assay; endocannabinoid; lipid; molecular interaction; optical measurement; phospholipids

Mesh:

Substances:

Year:  2018        PMID: 30463988      PMCID: PMC6314248          DOI: 10.1194/jlr.D089938

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  30 in total

1.  Measurement of aptamer-protein interactions with back-scattering interferometry.

Authors:  Ian R Olmsted; Yi Xiao; Minseon Cho; Andrew T Csordas; Jonathan H Sheehan; Jens Meiler; H Tom Soh; Darryl J Bornhop
Journal:  Anal Chem       Date:  2011-11-08       Impact factor: 6.986

2.  Binding isotope effects.

Authors:  Katarzyna Swiderek; Piotr Paneth
Journal:  Chem Rev       Date:  2013-07-12       Impact factor: 60.622

3.  A single receptor encoded by vzg-1/lpA1/edg-2 couples to G proteins and mediates multiple cellular responses to lysophosphatidic acid.

Authors:  N Fukushima; Y Kimura; J Chun
Journal:  Proc Natl Acad Sci U S A       Date:  1998-05-26       Impact factor: 11.205

4.  Origin and prediction of free-solution interaction studies performed label-free.

Authors:  Darryl J Bornhop; Michael N Kammer; Amanda Kussrow; Robert A Flowers; Jens Meiler
Journal:  Proc Natl Acad Sci U S A       Date:  2016-03-09       Impact factor: 11.205

5.  GPCR-radioligand binding assays.

Authors:  Colleen A Flanagan
Journal:  Methods Cell Biol       Date:  2016-02-10       Impact factor: 1.441

Review 6.  Lysophospholipid receptor nomenclature review: IUPHAR Review 8.

Authors:  Yasuyuki Kihara; Michael Maceyka; Sarah Spiegel; Jerold Chun
Journal:  Br J Pharmacol       Date:  2014-07-12       Impact factor: 8.739

7.  An experimental check of backscattering interferometry.

Authors:  Michael M Baksh; M G Finn
Journal:  Sens Actuators B Chem       Date:  2016-12-12       Impact factor: 7.460

8.  Structural insights into ligand recognition by the lysophosphatidic acid receptor LPA6.

Authors:  Reiya Taniguchi; Asuka Inoue; Misa Sayama; Akiharu Uwamizu; Keitaro Yamashita; Kunio Hirata; Masahito Yoshida; Yoshiki Tanaka; Hideaki E Kato; Yoshiko Nakada-Nakura; Yuko Otani; Tomohiro Nishizawa; Takayuki Doi; Tomohiko Ohwada; Ryuichiro Ishitani; Junken Aoki; Osamu Nureki
Journal:  Nature       Date:  2017-08-09       Impact factor: 49.962

Review 9.  Lysophospholipid receptors in drug discovery.

Authors:  Yasuyuki Kihara; Hirotaka Mizuno; Jerold Chun
Journal:  Exp Cell Res       Date:  2014-12-08       Impact factor: 3.905

Review 10.  LPA receptor signaling: pharmacology, physiology, and pathophysiology.

Authors:  Yun C Yung; Nicole C Stoddard; Jerold Chun
Journal:  J Lipid Res       Date:  2014-03-18       Impact factor: 5.922

View more
  8 in total

1.  Label-free Quantification of Direct Protein-protein Interactions with Backscattering Interferometry.

Authors:  Seher Abbas; Karl-Wilhelm Koch
Journal:  Bio Protoc       Date:  2021-12-20

Review 2.  Lysophosphatidic Acid Signalling in Nervous System Development and Function.

Authors:  Eric Birgbauer
Journal:  Neuromolecular Med       Date:  2020-11-05       Impact factor: 3.843

3.  A Novel Agonist of the Type 1 Lysophosphatidic Acid Receptor (LPA1), UCM-05194, Shows Efficacy in Neuropathic Pain Amelioration.

Authors:  Inés González-Gil; Debora Zian; Henar Vázquez-Villa; Gloria Hernández-Torres; R Fernando Martínez; Nora Khiar-Fernández; Richard Rivera; Yasuyuki Kihara; Isabel Devesa; Sakthikumar Mathivanan; Cristina Rosell Del Valle; Emma Zambrana-Infantes; María Puigdomenech; Giovanni Cincilla; Melchor Sanchez-Martinez; Fernando Rodríguez de Fonseca; Antonio V Ferrer-Montiel; Jerold Chun; Rubén López-Vales; María L López-Rodríguez; Silvia Ortega-Gutiérrez
Journal:  J Med Chem       Date:  2019-12-16       Impact factor: 7.446

4.  Signaling lipids as diagnostic biomarkers for ocular surface cicatrizing conjunctivitis.

Authors:  Antonio Di Zazzo; Wei Yang; Marco Coassin; Alessandra Micera; Marco Antonini; Fabrizio Piccinni; Maria De Piano; Isabelle Kohler; Amy C Harms; Thomas Hankemeier; Stefano Boinini; Alireza Mashaghi
Journal:  J Mol Med (Berl)       Date:  2020-04-20       Impact factor: 4.599

5.  Lysophosphatidic acid (LPA)-antibody (504B3) engagement detected by interferometry identifies off-target binding.

Authors:  Manisha Ray; Yasuyuki Kihara; Darryl J Bornhop; Jerold Chun
Journal:  Lipids Health Dis       Date:  2021-04-14       Impact factor: 3.876

6.  Ponesimod inhibits astrocyte-mediated neuroinflammation and protects against cingulum demyelination via S1P1 -selective modulation.

Authors:  Yasuyuki Kihara; Deepa Jonnalagadda; Yunjiao Zhu; Manisha Ray; Tony Ngo; Carter Palmer; Richard Rivera; Jerold Chun
Journal:  FASEB J       Date:  2022-02       Impact factor: 5.834

7.  Novel Antagonist of the Type 2 Lysophosphatidic Acid Receptor (LPA2), UCM-14216, Ameliorates Spinal Cord Injury in Mice.

Authors:  Nora Khiar-Fernández; Debora Zian; Henar Vázquez-Villa; R Fernando Martínez; Andrea Escobar-Peña; Román Foronda-Sainz; Manisha Ray; Maria Puigdomenech-Poch; Giovanni Cincilla; Melchor Sánchez-Martínez; Yasuyuki Kihara; Jerold Chun; Rubèn López-Vales; María L López-Rodríguez; Silvia Ortega-Gutiérrez
Journal:  J Med Chem       Date:  2022-08-10       Impact factor: 8.039

8.  Unlabeled lysophosphatidic acid receptor binding in free solution as determined by a compensated interferometric reader.

Authors:  Manisha Ray; Kazufumi Nagai; Yasuyuki Kihara; Amanda Kussrow; Michael N Kammer; Aaron Frantz; Darryl J Bornhop; Jerold Chun
Journal:  J Lipid Res       Date:  2020-06-08       Impact factor: 5.922

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.